期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 19, 期 10, 页码 1514-1517出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2013.07.013
关键词
Post-transplantation lymphoproliferative disorder; Allogeneic blood or marrow transplantation; Post-transplantation cyclophosphamide; Graft-versus-host disease prophylaxis
资金
- National Cancer Institute [P01CA15396, P50CA96888, P30CA006973, T32HL7525]
Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations. (C) 2013 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据